Early assessment of minimal residual disease identifies patients at very high relapse risk in NPM-ALK–positive anaplastic large-cell lymphoma
Open Access
- 16 January 2014
- journal article
- clinical trial
- Published by American Society of Hematology in Blood
- Vol. 123 (3), 334-337
- https://doi.org/10.1182/blood-2013-09-526202
Abstract
Key Points Early MRD positivity in NPM-ALK–positive ALCL correlates with a very high relapse risk and inferior survival.Keywords
This publication has 20 references indexed in Scilit:
- Use of minimal disseminated disease and immunity to NPM-ALK antigen to stratify ALK-positive ALCL patients with different prognosisLeukemia, 2012
- Prognostic Impact of Morphologic and Phenotypic Features of Childhood ALK-Positive Anaplastic Large-Cell Lymphoma: Results of the ALCL99 StudyJournal of Clinical Oncology, 2011
- Distribution of NPM1‐ALK and X‐ALK fusion transcripts in paediatric anaplastic large cell lymphoma: a molecular–histological correlationBritish Journal of Haematology, 2009
- Impact of the Methotrexate Administration Dose on the Need for Intrathecal Treatment in Children and Adolescents With Anaplastic Large-Cell Lymphoma: Results of a Randomized Trial of the EICNHL GroupJournal of Clinical Oncology, 2009
- Intensive chemotherapy for systemic anaplastic large cell lymphoma in children and adolescents: Final results of children's cancer group study 5941Pediatric Blood & Cancer, 2009
- Prognostic significance of circulating tumor cells in bone marrow or peripheral blood as detected by qualitative and quantitative PCR in pediatric NPM-ALK–positive anaplastic large-cell lymphomaBlood, 2007
- Childhood anaplastic large cell lymphoma has a high incidence of ALK gene rearrangement as determined by immunohistochemical staining and fluorescent in situ hybridisation: a genetic and pathological correlation*British Journal of Haematology, 2005
- Anaplastic large cell lymphoma treated with a leukemia‐like therapyCancer, 2005
- Prevalence and clinical implications of bone marrow involvement in pediatric anaplastic large cell lymphomaLeukemia, 2005
- Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90Blood, 2001